Clinical Trial Update: Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating toripalimab plus chidamide for relapsed/refractory peripheral T-cell lymphoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: PTCL | Phase 2 | Status: ACTIVE_NOT_RECRUITING